- This event has passed.
6th World Congresses on Controversies in Multiple Myeloma (COMy)
October 3, 2020 @ 3:30 pm - October 4, 2020 @ 7:30 pm CDT
|
Day 1: Saturday October 3, 2020 – All time CET |
|
|
15:30-17:00 |
Session 1: Smoldering myeloma: what’s next? |
Welcome address by congress Co-Chairs
How to define high risk smoldering myeloma Irene Ghobrial, USA
How to treat high risk smoldering myeloma Maria Victoria Mateos, Spain
Novel induction regimens Philippe Moreau, France
Maintenance therapy Graham Jackson, UK
Role and perspectives of MRD in myeloma Jesus San Miguel, Spain
Round table discussion
Jesus San Miguel, Spain, Herve Avet-Loiseau, France, Bruno Paiva, Spain, Kwee Yong, UK
|
Round table discussion |
|
|
17:00-18:30 |
Session 2: Therapy of transplant eligible patients |
|
Round table discussion |
|
|
18:30-19:30 |
Session 3: Plenary lecture |
|
19:30-20:30 |
Industry sponsored symposium (GSK) |
|
Day 2: Sunday October 4, 2020 – All time CET |
|
|
09:00-10:30 |
Session 4: Therapy of transplant ineligible patients |
Frailty assessment
Sonja Zweegman, The Netherland
Novel regimens in elderly patients Thierry Facon, France
Round table discussion
COMy Online 2020 Scientific Program
Sonja Zweegman, The Netherland, Thierry Facon, France, Alessandra Larocca, Italy, Maria Victoria Mateos, Spain
|
10:30-12:00 |
Session 5: Selected oral communications |
|
UPDATED PHASE 1B RESULTS FROM CARTITUDE-1: A PHASE 1B/2 STUDY OF JNJ-4528 CAR-T CELL THERAPY IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM) Presenter: Andrzej Jakubowiak, USA DREAMM-2: BELANTAMAB MAFODOTIN (BELAMAF) IN PATIENTS WITH MULTIPLE MYELOMA REFRACTORY TO PROTEASOME INHIBITORS, IMMUNOMODULATORY AGENTS, AND REFRACTORY/INTOLERANT TO ANTI-CD38 MAB, INCLUDING SUBGROUPS WITH RENAL IMPAIRMENT (RI) AND HIGH-RISK (HR) CYTOGENETICS DREAMM-5: PLATFORM TRIAL EVALUATING BELANTAMAB MAFODOTIN (A BCMA- DIRECTED IMMUNO-CONJUGATE) IN COMBINATION WITH NOVEL AGENTS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) FINAL ANALYSIS OF A PHASE I-b STUDY OF ISATUXIMAB COMBINED WITH CARFILZOMIB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): (NCT-02332850) Presenter: Tom Martin, USA OUTCOMES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS TREATED WITH IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) IN ROUTINE CLINICAL PRACTICE REMAIN COMPARABLE TO THE OUTCOMES REPORTED IN THE PHASE 3 TOURMALINE- MM1 STUDY Presenter: Xavier Leleu, France HORIZON (OP-106): MELFLUFEN PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO POMALIDOMIDE AND/OR AN ANTI-CD38 MONOCLONAL ANTIBODY (MAB) – FINAL PRIMARY ANALYSIS ORAL IXAZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (IRD) VERSUS PLACEBO-RD FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS INELIGIBLE FOR TRANSPLANT: THE MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TOURMALINE MM2 TRIAL Presenter: Thierry Facon, France |
|
|
12:30-14:00 |
Industry sponsored symposium (Sanofi) |
COMy Online 2020 Scientific Program
|
14:00-15:30 |
Session 6: Therapy of relapsed/refractory myeloma |
Anti-CD38-based combinations Saad Usmani, USA
IMiDs: past, present and future Xavier Leleu, France
Bispecific antibodies Luciano Costa, USA
CAR-T Cells Noopur Raje, USA
Round table discussion
Luciano Costa, USA, Noopur Raje, USA, Salomon Manier, France, Sagar Lonial, USA
Multiple Myeloma Excellence Award ceremony Presented to: Saad Usmani, USA by Congress Co-Chairs
Multiple Myeloma Excellence Award lecture Saad Usmani, USA
Management of Al amyloidosis: what’s new? Giampaolo Merlini, Italy
Round table discussion Giampaolo Merlini, Italy
|
Round table discussion |
|
|
15:30-17:00 |
Session 7: Immunotherapy for myeloma |
|
17:00-18:00 |
Session 8: Plenary lecture |
|
18:00-19:30 |
Industry sponsored symposium (Adaptive Biotechnologies) |